For instance, small molecule inhibitors targeting HSP90B1 or agents that modulate SYNCRIP’s RNA-binding activity could be explored to simultaneously disrupt metabolic adaptation and correct immune dysfunction in EMs. The gene discussed is SYNCRIP; the disease is immune system disorder.